Circulating and disseminated tumor cells

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1623-1626

  Braun, Stephan ^a   Naume, Bjørn ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER HORMONE THERAPY; CELL POPULATION; CELL SURVIVAL; CLINICAL TRIAL; HUMAN; IMMUNOCYTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; BONE MARROW; BREAST TUMOR; FEMALE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC AGENTS; BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM CIRCULATING CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 15544388390     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.073     Document Type: Review

References (47)

1. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 4:448-456, 2004
2. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893-895, 1977
3. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
4. van de Vijver MJ, He YD, van 't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
5. Bernards R, Weinberg RA: Metastasis genes: A progression puzzle. Nature 418:823-824, 2002
6. Schmidt-Kittler O, Ragg T, Daskalakis A, et al: From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100:7737-7742, 2003
7. Klein CA, Blankenstein TJF, Schmidt-Kittler O, et al: Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360:683-689, 2002
8. Klein CA, Seidl S, Petat-Dutter K, et al: Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20:387-392, 2002
9. Al-Hajj M, Becker MW, Wicha M, et al: Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43-47, 2004
10. Dontu G, Al-Hajj M, Abdallah WM, et al: Stem cells in normal breast development and breast cancer. Cell Prolif 36:59-72, 2003 (suppl 1)
11. Pierga J-Y, Bonneton C, Vincent-Salomon A, et al: Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:1392-1400, 2004
12. Wiedswang G, Borgen E, Karesen R, et al: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469-3478, 2003
13. Gebauer G, Fehm T, Merkle E, et al: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: Clinical outcome during long-term follow-up. J Clin Oncol 19:3669-3674, 2001
14. Gerber B, Krause A, Muller H, et al: Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19:960-971, 2001
15. Braun S, Pantel K, Müller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 342:525-533, 2000
16. Mansi JL, Gogas H, Bliss JM, et al: Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up. Lancet 354:197-202, 1999
17. Diel IJ, Kaufmann M, Costa SD, et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652-1664, 1996
18. Borgen E, Naume B, Nesland JM, et al: Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1:377-388, 1999
19. Braun S, Müller M, Hepp F, et al; Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 90:1099-1100, 1998
20. Pantel K, Schlimok G, Angstwurm M, et al: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3:165-173, 1994
21. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 20:3404-3412, 2002
22. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 278:1054-1059, 1997
23. Fields KK, Elfenbein GJ, Trudeau WL, et al: Clinical significance of bone marrow metastases as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 14:1868-1876, 1996
24. Datta YH, Adams PT, Drobyski WR: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475-482, 1994
25. Zippelius A, Lutterbuse R, Riethmuller G, et al: Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells. Clin Cancer Res 6:2741-2750, 2000
26. Ruud P, Fodstad Ø, Hovig E: Identification of a novel CK-19 pseudo-gene that may interfere with reverse-transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer 80:119-125, 1999
27. Bostick PJ, Chatterjee S, Chi DD, et al: Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16:2632-2640, 1998
28. Zippelius A, Kufer P, Honold G, et al: Limitations of reverse transcriptase-polymerase chain reaction for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15:2701-2708, 1997
29. Naume N, Wiedswang G, Borgen E, et al: Clinical significance of isolated tumor cells inperipheral blood in breast cancer patients three years after diagnosis: Comparison between analysis of peripheral blood and bone marrow. Proc Am Soc Clin Oncol 23:844, 2004 (abstr 9554)
30. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004
31. Reimers N, Zafrakas K, Assmann V, et al: Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10:3422-3428, 2004
32. Hemsen A, Riethdorf L, Brunner N, et al: Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 107:903-909, 2003
33. Braun S, Heumos I, Schlimok G, et al: ErbB2 over-expression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61:1890-1895, 2001
34. Braun S, Hepp F, Sommer HL, et al: Tumor antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease. Int J Cancer 84:1-5, 1999
35. Pantel K, Schlimok G, Braun S, et al: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424, 1993
36. Pantel K, Schlimok G, Kutter D, et al: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 51:4712-4715, 1991
37. Hayes DF, Walker TM, Singh B, et al: Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 21:1111-1117, 2002
38. Racila E, Euhus D, Weiss AJ, et al: Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 95:4589-4594, 1998
39. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393-9398, 2004
40. Fehm T, Sagalowsky A, Clifford E, et al: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8:2073-2084, 2002
41. Schlimok G, Funke I, Bock B, et al: Epithelial tumor cells in bone marrow of patients with colorectal cancer: Immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 8:831-837, 1990
42. Braun S, Hepp F, Kentenich CRM, et al: Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5:3999-4004, 1999
43. Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003
44. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
45. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
46. Wiedswang G, Borgen E, Kåresen R, et al: Isolated tumor cells in bone marrow 3 years after diagnosis in disease free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10:5342-5348, 2004
47. Janni W, Hepp F, Rjosk D, et al: The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 92:46-53, 2001